Fabio Schutz on Twitter: "JAEVILIN Renal 101 preliminary results presented by Dr. Motzer. Double the ORR with Avelumab+Axitinib, and improved PFS. Overall population and PDL1 positive poliarquia with similar benefit. OS still
Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) - UROONCO Kidney Cancer
Updates ASCO GU 2019 - mRCC
Cancers | Free Full-Text | Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens
Emerging Combination Therapies in Renal-Cell Carcinoma: Applying the Lessons from Clinical Trials to Clinical Practice - Journal of Oncology Navigation & Survivorship
Results from JAVELIN Renal 101 clinical trial - avelumab plus axitinib combination for advanced kidney cancer - Action Kidney Cancer
Immunotherapy Combinations Revolutionize the Management of Advanced Renal Cell Carcinoma
ASCO 2021: Association Between Neutrophil-to-Eosinophil Ratio (NER) and Efficacy Outcomes in the JAVELIN Renal 101 Study
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | Nature Medicine
Dr. Elias reviews Keynote 426 and JAVELIN Renal 101 clinical trials – UT Southwestern Internal Medicine Journal Watch
Cancers | Free Full-Text | Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101 - Uemura - 2020 - Cancer Science - Wiley Online Library
Immunotherapy Strategies in Renal Cell Carcinoma - The ASCO Post
ESMO 2019: Efficacy and Biomarker Analysis of Patients with Advanced Renal Cell Carcinoma with Sarcomatoid Histology: Subgroup Analysis from the Phase III JAVELIN Renal 101 Trial – Philippine Endourological Society
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - ScienceDirect
First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology | Scientific Reports
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM
ESMO 2018: JAVELIN Renal 101: A Randomized, Phase 3 Study of Avelumab + Axitinib vs Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial | Request PDF
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - ScienceDirect
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101 - Uemura - 2020 - Cancer Science - Wiley Online Library
ASCO GU 2021: Efficacy and Safety of Avelumab plus Axitinib (A + Ax) Versus Sunitinib (S) in Elderly Patients with Advanced Renal Cell Carcinoma (aRCC): Extended Follow-up Results from JAVELIN Renal 101
ASCO GU 2021: Efficacy and Safety of Avelumab plus Axitinib (A + Ax) Versus Sunitinib (S) in Elderly Patients with Advanced Renal Cell Carcinoma (aRCC): Extended Follow-up Results from JAVELIN Renal 101
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma - ScienceDirect
Safety and Efficacy Data: The JAVELIN Renal 101 Trial
